Frontiers in oncology · 2026
Lobular breast cancer and prognosis: what should we tell patients?
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kulasegaran Tivya, Beecher Kate, Kinnon Pamela, Lakhani Sunil R, Simpson Peter T, McCart Reed Amy E
Аннотация
BACKGROUND: Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer. It accounts for up to 15% of all breast cancer diagnoses, and there is an increasing population of people living with a diagnosis of 'lobular'. ILC has historically been understudied and is underrepresented in clinical trials. Presenting with pathology features typical of a good prognosis (oestrogen receptor-positive, HER2-negative, grade 2), a diagnosis of ILC can be framed as one with a 'good outcome'. But whether the data support this over time remains to be seen.
METHODS: We present a comprehensive narrative review to ascertain whether ILC has a better outcome than invasive carcinoma of no special type (IC-NST).
RESULTS: A number of the research studies analysed showed that ILC can have a better outcome at 5 years and still have a poorer outcome over time, whilst others showed that IC-NST has a poor outcome early, which is maintained over time.
CONCLUSIONS: We discuss limitations and confounders and, critically, give voice to the people living with a lobular breast cancer diagnosis.
METHODS: We present a comprehensive narrative review to ascertain whether ILC has a better outcome than invasive carcinoma of no special type (IC-NST).
RESULTS: A number of the research studies analysed showed that ILC can have a better outcome at 5 years and still have a poorer outcome over time, whilst others showed that IC-NST has a poor outcome early, which is maintained over time.
CONCLUSIONS: We discuss limitations and confounders and, critically, give voice to the people living with a lobular breast cancer diagnosis.